Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Intra-abdominal Infection Clear all

Conditions: Necrotizing Pancreatitis
Interventions: Using ABTHERA Advance without a Wittmann Patch; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Sepsis
Interventions: Frailty Measurements, Modified Minnesota Leisure Time Activities, Computed tomography morphometrics, Mobility Monitors; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
Interventions: TriVerity; Diagnostic Test
Lead sponsor: Inflammatix; Industry
Eligibility: 18 Years and older
Enrollment: 1,441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more

Conditions: Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions: Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more

Conditions: Gram-negative Bacterial Infections
Interventions: ATM-AVI, BAT; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 9 Months to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Diego, California • New York, New York • Memphis, Tennessee

Conditions: Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions: ATM-AVI, MTZ, MER, COL; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Tucson, Arizona • Torrance, California • Springfield, Illinois

Conditions: Complicated Intra-abdominal Infection
Interventions: TP-434, Ertapenem, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Long Beach, California • Denver, Colorado • Detroit, Michigan + 2 more

Conditions: Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions: tigecycline, ceftriaxone sodium + metronidazole; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 46
States / cities: Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-201 and metronidazole, Meropenem; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more

Conditions: Complicated Intra-Abdominal Infection
Interventions: CAZ-AVI, Metronidazole, Meropenem; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more

Conditions: Infections, Intestinal
Interventions: Drug: GSK2251052, Meropenem, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Mobile, Alabama • Long Beach, California • Torrance, California + 9 more

Conditions: Nausea, Vomiting
Interventions: Normal Saline Irrigation; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complicated Intra-abdominal Infections (cIAI)
Interventions: IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 2 more

Search by objective public record fields.

ABTHERA ADVANCE™ Use Without Wittman Patch

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

Intra-abdominal at Cesarean Section: A Randomized Controlled Trial

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)